<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The treatment of <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> symptoms in patients with <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorders</z:e> is a complex challenge </plain></SENT>
<SENT sid="1" pm="."><plain>Antipsychotic medications in these individuals may be associated with <z:hpo ids='HP_0002071'>extrapyramidal symptoms</z:hpo> (EPS), worsening of <z:hpo ids='HP_0000716'>depression</z:hpo>, and functional impairment </plain></SENT>
<SENT sid="2" pm="."><plain>Atypical <z:chebi fb="0" ids="35476">antipsychotics</z:chebi> such as <z:chebi fb="0" ids="8707">quetiapine</z:chebi> and <z:chebi fb="0" ids="8871">risperidone</z:chebi> are associated with a decreased incidence of adverse events such as EPS </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of this study was to compare the efficacy and tolerability of <z:chebi fb="0" ids="8707">quetiapine</z:chebi> and <z:chebi fb="0" ids="8871">risperidone</z:chebi> for the treatment of depressive symptoms in outpatients with <z:hpo ids='HP_0000709'>psychosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: In this 4-month, multicenter, open-label trial, patients were randomly assigned in a 3:1 ratio of <z:chebi fb="0" ids="8707">quetiapine</z:chebi> to <z:chebi fb="0" ids="8871">risperidone</z:chebi>, and both drugs were flexibly dosed </plain></SENT>
<SENT sid="5" pm="."><plain>Eligible patients had <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychoses</z:e> and demonstrated 1 of several <z:chebi fb="4" ids="38624">DSM</z:chebi>-IV diagnoses, including <z:e sem="disease" ids="C0036337" disease_type="Mental or Behavioral Dysfunction" abbrv="">schizoaffective disorder</z:e>, <z:e sem="disease" ids="C0853193" disease_type="Mental or Behavioral Dysfunction" abbrv="">bipolar I disorder</z:e>, <z:e sem="disease" ids="C1269683" disease_type="Mental or Behavioral Dysfunction" abbrv="MDD">major depressive disorder</z:e>, <z:e sem="disease" ids="C0011251" disease_type="Mental or Behavioral Dysfunction" abbrv="">delusional disorder</z:e>, Alzheimer's <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:e sem="disease" ids="C0036358" disease_type="Mental or Behavioral Dysfunction" abbrv="">schizophreniform disorder</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, and <z:e sem="disease" ids="C0740858" disease_type="Mental or Behavioral Dysfunction" abbrv="">substance abuse</z:e> <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients were classified as mood disordered if they had <z:hpo ids='HP_0007302'>bipolar disorder</z:hpo>, <z:e sem="disease" ids="C1269683" disease_type="Mental or Behavioral Dysfunction" abbrv="MDD">major depressive disorder</z:e>, or <z:e sem="disease" ids="C0036337" disease_type="Mental or Behavioral Dysfunction" abbrv="">schizoaffective disorder</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Efficacy was assessed using the Positive and Negative Syndrome Scale and the Clinical Global Impressions scale </plain></SENT>
<SENT sid="8" pm="."><plain>The Hamilton Rating Scale for <z:hpo ids='HP_0000716'>Depression</z:hpo> (HAM-D) was used to assess the level of depressive symptoms </plain></SENT>
<SENT sid="9" pm="."><plain>The primary tolerability assessment was presence or absence of substantial EPS, defined as EPS severe enough to require an alteration in treatment </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: A total of 554 patients were randomly assigned to <z:chebi fb="0" ids="8707">quetiapine</z:chebi> and 175 to <z:chebi fb="0" ids="8871">risperidone</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Mean doses at 16 weeks were 318 mg for <z:chebi fb="0" ids="8707">quetiapine</z:chebi> and 4.4 mg for <z:chebi fb="0" ids="8871">risperidone</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Although both agents produced improvements in mean HAM-D scores, <z:chebi fb="0" ids="8707">quetiapine</z:chebi> produced a greater improvement than <z:chebi fb="0" ids="8871">risperidone</z:chebi> in <z:hpo ids='HP_0000001'>all</z:hpo> patients (p =.0015) </plain></SENT>
<SENT sid="13" pm="."><plain>Within the mood-diagnosed population, incidences of both substantial EPS (p =.001) and at least moderate EPS (p =.0373) occurred significantly less frequently among patients taking <z:chebi fb="0" ids="8707">quetiapine</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>For patients with non-mood diagnoses, incidences of substantial EPS were fewer for patients taking <z:chebi fb="0" ids="8707">quetiapine</z:chebi> than for those taking <z:chebi fb="0" ids="8871">risperidone</z:chebi> (p =.062); however, this was not statistically significant </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: These results suggest that <z:chebi fb="0" ids="8707">quetiapine</z:chebi> may be a useful agent in the management of depressive symptoms in patients with <z:hpo ids='HP_0000709'>psychosis</z:hpo> </plain></SENT>
</text></document>